복합화학요법을 받은 미만성 거대 B세포 림프종 환자의 호중구감소증 발생에 영향을 미치는 요인: 환자-대조군 연구
Factors Associated with Chemotherapy-induced Neutropenia in Diffuse Large B-cell Lymphoma Patients Undergoing Combination Chemotherapy: A Case-Control Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to identify the factors associated with chemotherapy-induced neutropenia (CIN) in diffuse large B-cell lymphoma (DLBCL) patients undergoing combination chemotherapy. Methods: A total of 111 patients with DLBCL participated in this study at C University Hospital. The CIN group consisted of patients with an absolute neutrophil count (ANC) lower than 1,000 cells/μL. Clinical factors, the level of depression, and the level of healthy lifestyle were measured on the chemotherapy administration day, and the ANC was measured on the next follow-up day. Results: Binary logistic regression analysis showed that the factors associated with CIN in DLBCL were the presence of B symptoms at diagnosis (β=4.69) and low-risk CIN regimen (β=0.10) among clinical factors, and the level of healthy lifestyle (β=0.17). Conclusion: Oncology nurses have to focus on the patients vulnerable to CIN having B symptoms at diagnosis, receiving a low-risk CIN regimen, and showing non-adherence to healthy lifestyle practice. Administration of granulocyte colony-stimulating factor can be considered for the patients receiving low-risk CIN regimen to reduce CIN. Education programs including healthy lifestyle practice to improve the immune system should be applied to the DLBCL patients.
Abstract
Purpose: This study aimed to identify the factors associated with chemotherapy-induced neutropenia (CIN) in diffuse large B-cell lymphoma (DLBCL) patients undergoing combination chemotherapy. Methods: A total of 111 patients with DLBCL participated in this study at C University Hospital. The CIN group consisted of patients with an absolute neutrophil count (ANC) lower than 1,000 cells/μL. Clinical factors, the level of depression, and the level of healthy lifestyle were measured on the chemotherapy administration day, and the ANC was measured on the next follow-up day. Results: Binary logistic regression analysis showed that the factors associated with CIN in DLBCL were the presence of B symptoms at diagnosis (β=4.69) and low-risk CIN regimen (β=0.10) among clinical factors, and the level of healthy lifestyle (β=0.17). Conclusion: Oncology nurses have to focus on the patients vulnerable to CIN having B symptoms at diagnosis, receiving a low-risk CIN regimen, and showing non-adherence to healthy lifestyle practice. Administration of granulocyte colony-stimulating factor can be considered for the patients receiving low-risk CIN regimen to reduce CIN. Education programs including healthy lifestyle practice to improve the immune system should be applied to the DLBCL patients.
참고문헌 (30)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- van Leeuwen MT, "Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006", Int J Cancer, 135, pp.2146~2156 (2014)
- Pfreundschuh M, "CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma:6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group", Lancet Oncol, 12, pp.1013~1022 (2011)
- Aapro MS, "2010 update of EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours", Eur J Cancer, 47, pp.8~32 (2011)
- Boccia R, "Chemotherapy-induced neutropenia and febrile neutropenia in the US : a beast of burden that needs to be tamed?", Oncologist, 27, pp.625~636 (2022)
- Lalami Y, "Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data", Crit Rev Oncol Hematol, 120, pp.163~179 (2017)
- 최용원, "Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP", Journal of Korean Medical Science, 29(11), pp.1493~1500 (2014), 대한의학회
- Usami E, "Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting", Mol Clin Oncol, 4, pp.591~596 (2016)
- Lyman GH, "Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy : a systematic review", Crit Rev Oncol Hematol, 90, pp.190~199 (2014)
- Bartlett DB, "Habitual physical activity is associated with the maintenance of neutrophil migratory dynamics in healthy older adults", Brain Behav Immun, 56, pp.12~20 (2016)
- Tavakoli-Ardakani M, "Effect of pretransplant depression on neutrophil recovery following hematopoietic stem cell transplantation", Transpl Res Risk Manag, 11, pp.1~9 (2019)
- Howard R, "Sociodemographic and lifestyle factors associated with the neutrophil-to-lymphocyte ratio", Ann Epidemiol, 38, pp.11~21.e6 (2019)
- "American Society of Clinical Oncology"[URL]
- Freites-Martinez A, "Using the common terminology criteria for adverse events (CTCAE – Version 5.0) to evaluate the severity of adverse events of anticancer therapies", Actas Dermosifiliogr (Engl Ed), 112, pp.90~92 (2021)
- Hassan BA, "Updates on cancer treatment", pp.1~23 (2015), IntechOpen
- Oken MM, "Toxicity and response criteria of the Eastern Cooperative Oncology Group", Am J Clin Oncol, 5, pp.649~655 (1982)
- Lee M, "Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim", Asia Pac J Clin Oncol, 15, pp.231~237 (2019)
- Quan H, "Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries", Am J Epidemiol, 173, pp.676~682 (2011)
- Carbone PP, "Report of the committee on Hodgkin’s disease staging classification", Cancer Res, 31, pp.1860~1861 (1971)
- Becker PS, "NCCN guidelines insights: hematopoietic growth factors, version 1.2020", J Natl Compr Canc Netw, 18, pp.12~22 (2020)
- Lyman GH, "Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy", Cancer, 117, pp.1917~1927 (2011)
- Walker SN, "The Health-Promoting Lifestyle Profile : development and psychometric characteristics", Nurs Res, 36, pp.76~81 (1987)
- 서현미, "노인의 건강증진행위 모형 구축", 박사, 간호학, pp.2001
- 성형모, "한국어판 백 우울 설문지 2판의 신뢰도 및 타당도 연구", 생물치료정신의학, 14(2), pp.201~212 (2008), 대한생물치료정신의학회
- Moghaddam SR, "The effect of leisure time regular exercise on neutrophil function, myeloperoxidase levels, and antioxidant capacity in middle-aged men", Med Sci J Islamic Azad Uni, 31, pp.413~424 (2021)
- Arends J, "ESPEN guidelines on nutrition in cancer patients", Clin Nutr, 36, pp.11~48 (2017)
- O’Malley M, "Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors", Oncology, 85, pp.216~222 (2013)
- Vusqa U, "Predictors and long-term outcomes for diffuse large B-cell lymphoma (DLBCL) patients undergoing surgery prior to systemic therapy:a nationwide analysis", Cureus, 14, pp.e24448~ (2022)
- Sharma R, "Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO", BMC Cancer, 9, pp.153~ (2009)
- Makihara K, "Influence of concomitant polypharmacy on docetaxel-induced febrile neutropenia", Cancer Diagn Progn, 1, pp.135~141 (2021)